3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
2
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Lung Cancer Metastatic
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
29
Carboplatin
15
Cisplatin
13
Nivolumab
12
atezolizumab
10
Radiotherapy
10
Paclitaxel
10
Ipilimumab
10
venetoclax
9
Pemetrexed
9
Docetaxel
9
durvalumab
8
Gemcitabine
8
fludarabine
7
Specimen Handling
7
Cyclophosphamide
7
Bevacizumab
7
tislelizumab
6
fludarabine phosphate
6
Trastuzumab
6
Practice Guidelines as Topic
6
Cetuximab
6
Biopsy
6
enzalutamide
5
Surveys and Questionnaires
5
Standard of Care
5
Radiosurgery
5
Magnetic Resonance Spectroscopy
5
Dexamethasone
5
Cytarabine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
evolocumab
×
90 days
×
Clear all
NCT03337698
2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2
Terminated
314 enrolled
31 charts
NCT05144529
2026-05-05
TOP2101
Duke University
Phase 2
Terminated
19 enrolled
16 charts